247 related articles for article (PubMed ID: 12911317)
1. Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance.
Renodon-Cornière A; Jensen LH; Nitiss JL; Jensen PB; Sehested M
Biochemistry; 2003 Aug; 42(32):9749-54. PubMed ID: 12911317
[TBL] [Abstract][Full Text] [Related]
2. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
3. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
4. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity.
Mao Y; Yu C; Hsieh TS; Nitiss JL; Liu AA; Wang H; Liu LF
Biochemistry; 1999 Aug; 38(33):10793-800. PubMed ID: 10451375
[TBL] [Abstract][Full Text] [Related]
5. Separation of bisdioxopiperazine- and vanadate resistance in topoisomerase II.
Sorensen TK; Grauslund M; Jensen PB; Sehested M; Jensen LH
Biochem Biophys Res Commun; 2005 Sep; 334(3):853-60. PubMed ID: 16053917
[TBL] [Abstract][Full Text] [Related]
6. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.
Danks MK; Warmoth MR; Friche E; Granzen B; Bugg BY; Harker WG; Zwelling LA; Futscher BW; Suttle DP; Beck WT
Cancer Res; 1993 Mar; 53(6):1373-9. PubMed ID: 8383009
[TBL] [Abstract][Full Text] [Related]
7. Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance.
Kingma PS; Burden DA; Osheroff N
Biochemistry; 1999 Mar; 38(12):3457-61. PubMed ID: 10090731
[TBL] [Abstract][Full Text] [Related]
8. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
[TBL] [Abstract][Full Text] [Related]
10. Interaction of human DNA topoisomerase II alpha with DNA: quantification by surface plasmon resonance.
Renodon-Cornière A; Jensen LH; Nitiss JL; Jensen PB; Sehested M
Biochemistry; 2002 Nov; 41(45):13395-402. PubMed ID: 12416984
[TBL] [Abstract][Full Text] [Related]
11. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl(2)(dexrazoxane) and cis-PtCl(2)(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186).
Hasinoff BB; Wu X; Yang Y
J Inorg Biochem; 2004 Apr; 98(4):616-24. PubMed ID: 15041241
[TBL] [Abstract][Full Text] [Related]
14. Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.
Hammonds TR; Foster SR; Maxwell A
J Mol Biol; 2000 Jul; 300(3):481-91. PubMed ID: 10884345
[TBL] [Abstract][Full Text] [Related]
15. Expression, purification and characterization of recombinant mitochondrial topoisomerase II of kinetoplastid Crithidia fasciculata in High-five insect cells.
Wang Y; Tsai YC; Urena-Rivera E; Chen J
Protein Expr Purif; 2008 Mar; 58(1):122-31. PubMed ID: 18068376
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the ATPase activity of topoisomerase II from Leishmania donovani and identification of residues conferring resistance to etoposide.
Sengupta T; Mukherjee M; Das A; Mandal C; Das R; Mukherjee T; Majumder HK
Biochem J; 2005 Sep; 390(Pt 2):419-26. PubMed ID: 15901238
[TBL] [Abstract][Full Text] [Related]
17. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells.
Hasinoff BB; Abram ME; Chee GL; Huebner E; Byard EH; Barnabé N; Ferrans VJ; Yu ZX; Yalowich JC
J Pharmacol Exp Ther; 2000 Nov; 295(2):474-83. PubMed ID: 11046078
[TBL] [Abstract][Full Text] [Related]
18. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
Ishida R; Hamatake M; Wasserman RA; Nitiss JL; Wang JC; Andoh T
Cancer Res; 1995 Jun; 55(11):2299-303. PubMed ID: 7757979
[TBL] [Abstract][Full Text] [Related]
19. A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage.
Thougaard AV; Langer SW; Hainau B; Grauslund M; Juhl BR; Jensen PB; Sehested M
Toxicology; 2010 Feb; 269(1):67-72. PubMed ID: 20079798
[TBL] [Abstract][Full Text] [Related]
20. Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alpha.
Wessel I; Jensen LH; Renodon-Corniere A; Sorensen TK; Nitiss JL; Jensen PB; Sehested M
FEBS Lett; 2002 Jun; 520(1-3):161-6. PubMed ID: 12044890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
